To investigate the immunological mechanisms underlying the enhanced tumor-specific immune responses, the effects of the combination therapy on the proportion of MDSCs (CD11b+Gr1+) and Tregs (CD4+FoxP3+ and CD4+FoxP3+ cells) were analyzed. The gene discussed is CD4; the disease is neoplasm.